Brief: Microbiotica Reports Positive Phase 1B Data For MB310
11/02/2026 10:41
Feb 11 (Reuters) - Flerie AB FLERIE.ST: FLERIE'S PORTFOLIO COMPANY MICROBIOTICA REPORTS POSITIVE PHASE 1B DATA FOR MB310 IN PATIENTS WITH ULCERATIVE COLITIS MICROBIOTICA'S DRUG CANDIDATE MB310, A PRECISION MICROBIOME MEDICINE, MET ITS PRIMARY AND SECONDARY OBJECTIVES DRUG CANDIDATE EXHIBITED A FAVOURABLE SAFETY PROFILE Source text: ID:nMFN8QZ3s4 Further company coverage: FLERIE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))